/ 2 items

#VRCA↓

RYTM/ 11/05/2025 · 9:57 AM

Pharma Stock Moves: Oppenheimer Downgrades Rhythm, New Buys on Vanda, Verrica, CervoMed, and Ventyx

Oppenheimer downgrades Rhythm Pharmaceuticals after major gains, while analysts issue fresh Buy ratings on Vanda, Verrica, CervoMed, and Ventyx highlighting key catalysts and growth potential.

VRCA/ 09/19/2025 · 9:19 AM

Verrica's Skin Infection Drug Ycanth Gains Approval in Japan

Verrica's drug Ycanth, which treats the common viral skin infection molluscum contagiosum, gained approval in Japan. This key approval immediately triggers a $10 million cash payment to Verrica, boosting their finances and supporting U.S. sales efforts.